For many, it represents the worst day of their life: The day they receive a cancer diagnosis. Hearing the words ring from a physician’s mouth. Having the world fade away. The mind spinning with the ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...

Sequential BCL2 inhibitor therapy shows initial responses but lacks durability, especially in patients exposed to both BTKi ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

Fixed-duration regimens of venetoclax combined with obinutuzumab (VO) or ibrutinib (VI) show efficacy similar to that of continuous ibrutinib monotherapy in the first-line treatment of chronic ...

Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.